Furthermore, upregulation of COX-2 and PGE2 has been identified in many human cancers and precancerous lesions, and COX-inhibitory drugs have shown protective effects in colorectal cancer (56, 57). This evidence concerns the gene PTGS2 and colorectal cancer.